echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > FDA Expands Junshi/Eli Lilly New Crown Neutralizing Antibody Emergency Authorization

    FDA Expands Junshi/Eli Lilly New Crown Neutralizing Antibody Emergency Authorization

    • Last Update: 2021-09-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 16, Eli Lilly announced that the US FDA has expanded its new coronavirus neutralizing antibodies bamlanivimab (700mg) and etesevimab (1400mg) emergency use authorization (EUA) in cooperation with Junshi for post-exposure prevention (PEP)


    FDA prevents COVID-19 immune infection

    This expanded authorization is based on data from BLAZE-2


    bamlanivimab (LY-CoV555) was discovered by AbCellera and developed by Eli Lilly.


    etesevimab (JS016 or LY-CoV016) is a recombinant fully human monoclonal neutralizing antibody that specifically binds to the receptor binding domain of the spike protein on the surface of SARS-CoV-2 with high affinity, and can effectively block the virus and host cells Binding of the surface receptor ACE2


    On June 25, 2021, the U.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.